Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies.
about
Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.Physical inactivity: a risk factor and target for intervention in renal care.The Diet and Haemodialysis Dyad: Three Eras, Four Open Questions and Four Paradoxes. A Narrative Review, Towards a Personalized, Patient-Centered Approach.Is low-protein diet a possible risk factor of malnutrition in chronic kidney disease patients?Chronic kidney disease and fragility fracture.Muscle wasting in chronic kidney disease.As we grow old: nutritional considerations for older patients on dialysis.Sarcopenia and relationships between muscle mass, measured glomerular filtration rate and physical function in patients with chronic kidney disease stages 3-5.Screening for muscle loss in patients established on peritoneal dialysis using bioimpedance.Hormonal changes in hemodialysis patients: Novel risk factors for mortality?Vitamin D, a modulator of musculoskeletal health in chronic kidney disease.NF-κB expression and its association with nutritional status in hemodialysis patients.Sarcopenia and its individual criteria are associated, in part, with mortality among patients on hemodialysis.Effect of Self-Reported Distress Thermometer Score on the Maximal Handgrip and Pinch Strength Measurements in Hemodialysis Patients.Efficacy and safety of whole body vibration in maintenance hemodialysis patients - A pilot study.Establishing a clinical phenotype for cachexia in end stage kidney disease - study protocol.Frailty and chronic kidney disease: current evidence and continuing uncertainties.Physical activity promotion for patients transitioning to dialysis using the "Exercise is Medicine" framework: a multi-center randomized pragmatic trial (EIM-CKD trial) protocol
P2860
Q30234751-BC7FD605-F63B-4F42-BF40-7DDA4C715518Q30238711-CE7BE9D7-BFD8-4467-92FF-FB572CFF68F5Q33616803-551A908C-E3F5-416B-929C-BE3EB12A7454Q37164355-4FB9C3F5-1381-4611-A2AE-C7849D73FB40Q37639872-6C64CBEC-DAFE-450E-98BE-4B161611B20AQ38784295-FF8C18AB-35D0-4EF7-959E-93E74B654960Q38840709-2EB11CEE-A69A-4261-A31E-C57F0D9F3B51Q38878535-24970CFF-3822-4040-8FEF-F88A78B82FD6Q39249156-B070AE8D-15C6-4229-95EC-EBFFD4B9B5A7Q39369109-81E59BBC-AEDE-4CDA-BC50-D0B2F8CFD257Q39413414-89E9BD8B-D34D-4DE0-A129-0E090E189940Q40563733-02B4F260-DC2A-4EC0-9816-F7E9D1E3E6D8Q45933573-0EE68A4C-504A-4AA5-9F29-6FA851139FF8Q47319384-78A502F5-FE9A-423D-88BF-9141DD042F31Q47377446-D092446E-7DB9-437C-9638-1D002C7B9FEBQ49194938-9ED92F95-E203-4725-A7DB-C08106FAD747Q55035811-21A0D310-8B32-416A-A404-91172F7F1525Q58747214-12FC69A8-C5CC-4568-9CD7-20F4B31AC69E
P2860
Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Muscle wasting in end-stage re ...... al novel treatment strategies.
@en
type
label
Muscle wasting in end-stage re ...... al novel treatment strategies.
@en
prefLabel
Muscle wasting in end-stage re ...... al novel treatment strategies.
@en
P2093
P2860
P356
P1476
Muscle wasting in end-stage re ...... al novel treatment strategies.
@en
P2093
Ferdinand von Walden
Gustavo A Nader
Juan Jesus Carrero
T Alp Ikizler
P2860
P304
P356
10.1093/NDT/GFV122
P407
P577
2015-04-24T00:00:00Z